Subscribe

What are you looking for?

Main Menu

明報新聞網

翰森製藥：阿美替尼於歐盟上市許可被撤銷

Future Wealths
Future Wealths
27 9 月, 2026
One Min Read
3 Views
0 Comments
翰森製藥（3692）公布，集團旗下產品阿美替尼（Aumseqa®）單藥治療於歐盟獲批上市的許可被撤銷。集團指出，決定乃於歐盟委員會啟動撤銷程序後作出，該程序據悉為阿斯利康就該上市許可於歐盟普通法院對歐盟委員會提起訴訟後，在未等待該撤銷訴訟結果的情況下啟動。

原文: https://finance.mingpao.com/fin/instantf/20260927/1790505115653/%E7%BF%B0%E6%A3%AE%E8%A3%BD%E8%97%A5-%E9%98%BF%E7%BE%8E%E6%9B%BF%E5%B0%BC%E6%96%BC%E6%AD%90%E7%9B%9F%E4%B8%8A%E5%B8%82%E8%A8%B1%E5%8F%AF%E8%A2%AB%E6%92%A4%E9%8A%B7%22%20target=%22blank

Last Update: 27 9 月, 2026

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept